The TP53 gene network in a postgenomic era

Human Mutation

Volumn 35, Issue 6, 2014, Pages 641-642

  Soussi, Thierry ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Cancer; Clinical; LSDB; Mutation nomenclature; Oncology; P53; Patient care; TP53; Tumor

Indexed keywords

ISOPROTEIN; PROTEIN P53; MDM2 PROTEIN, HUMAN; MDM4 PROTEIN, HUMAN; MICRORNA; MIRN125 MICRORNA, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; TP53 PROTEIN, HUMAN;

ACETYLATION; ADRENAL CORTEX CARCINOMA; ARTICLE; BREAST CANCER; CLINICAL FEATURE; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; GENE STRUCTURE; GENETIC DISORDER; GENETIC VARIABILITY; GENOME; GERMLINE MUTATION; HIGH THROUGHPUT SEQUENCING; HUMAN; NONHUMAN; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN METHYLATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RNA TRANSLATION; SOMATIC MUTATION; TUMOR GENE; UBIQUITINATION; GENE REGULATORY NETWORK; GENETICS; GENOMICS; HUMAN GENOME; METABOLISM; MISSENSE MUTATION; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

GENE REGULATORY NETWORKS; GENOME, HUMAN; GENOMICS; HUMANS; MICRORNAS; MUTATION, MISSENSE; NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84901030198     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22562     Document Type: Article

References (15)

1. Bisio A, Ciribilli Y, Fronza G, Inga A, Monti P. 2014. TP53 mutants in the tower of babel of cancer progression. Hum Mutat 35:689-701.
2. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. 2005. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19:2122-2137.
3. Candi E, Agostini M, Melino G, Bernassola F. 2014. How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. Hum Mutat 35:702-714.
4. Donehower LA. 2014. Insights into wild-type and mutant p53 functions provided by genetically engineered mice. Hum Mutat 35:715-727.
5. Eischen CM, Lozano G. 2014. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat 35:728-737.
6. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, et al. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819.
7. Kamihara J, Rana HQ, Garber JE. 2014. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat 35:654-662.
8. Leroy B, Andersson M, Soussi T. 2014a. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat 35:672-688.
9. Leroy B, Girard L, Minna JD, Gazdar AF, Soussi T. 2014b. Analysis of p53 mutation status in human cancer cell lines: a reassessment. Hum Mutat 35:756-765.
10. Malcikova J, Pavlova S, Kozubik KS, Pospisilova S. 2014. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia. Hum Mutat 35:663-671.
11. Nguyen TA, Menendez D, Resnick MA, Anderson CW. 2014. Mutant TP53 posttranslational modifications: challenges and opportunities. Hum Mutat 35:738-755.
12. Soussi T. 2003. Focus on the p53 gene and cancer: advances in TP53 mutation research. Hum Mutat 21:173-175.
13. Soussi T. 2014. Locus-specific databases in cancer: what future in a post-genomic era? The TP53 LSDB paradigm. Hum Mutat 35:643-653.
14. Soussi T, Leroy B, Taschner PEM. 2014. Recommendations for analyzing and reporting TP53 gene alterations in the high throughput sequencing era. Hum Mutat 35:766-778.
15. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305-316.